1.Reversal of Early Central Retinal Vein Occlusion by Alleviating Optic Nerve Edema with an Intravitreal Dexamethasone Implant.
Young Joo CHO ; Dong Hyun LEE ; Hae Min KANG ; Min KIM ; Hyoung Jun KOH
Korean Journal of Ophthalmology 2014;28(2):192-193
This case describes the reversal of early central retinal vein occlusion (CRVO) with disc swelling after intravitreal dexamethasone implant (Ozurdex) injection. A 44-year-old female presented with sudden-onset intermittent blurred vision in her left eye. Fundus examination revealed multiple retinal hemorrhages without macular edema (ME). Two weeks later, an increased number of retinal hemorrhages with severe disc swelling were noted with still no sign of ME. An intravitreal dexamethasone implant was injected. Five days later, there were improvements in disc swelling and retinal hemorrhage. One month later, her subjective visual symptoms were completely improved, and fundus examination revealed marked improvement along with almost complete resolution of disc swelling. Intravitreal dexamethasone implant injection may potentially change the natural course of CRVO progression and its various subsequent complications.
Adult
;
Dexamethasone/*administration & dosage
;
Drug Implants
;
Female
;
Glucocorticoids/*administration & dosage
;
Humans
;
Intravitreal Injections
;
Papilledema/*drug therapy
;
Retinal Vein/*drug effects
;
Retinal Vein Occlusion/*drug therapy
;
Treatment Outcome
2.Network pharmacology study of mechanism on xuesaitong injection against retinal vein occlusion.
Lin-Li WANG ; Xiao-Ping ZHAO ; Zhuan-You ZHAO ; Xiao-Hui FAN ; Zheng LI
China Journal of Chinese Materia Medica 2014;39(12):2322-2325
Retinal vein occlusion (RVO) is a common clinical disease causing vision loss. Risk factors such as diabetes, atherosclerosis are closely associated with RVO. Xuesaitong injection is used extensively in clinical treatment of RVO, however the mechanism is still unclear. In this study, we investigated the protective effect of Xuesaitong injection on RVO rat model. Using a compound-target network of Xuesaitong on anti-RVO constructed by literature mining, we aim to elucidate the multi-compound, multi-target effect of Xuesaitong injection. Fifteen potential targets of Xuesaitong injection associated with inflammation, angiogenesis, apoptosis, and coagulation were identified in this study. VEGF, IL-1beta and IL-6, three important targets in the compound-target network were further experimentally validated. This study provided experimental evidence for Xuesaitong injection being effective in treating RVO and a network view on its anti-RVO mode of action through a multi-compound and multiple-target mechanism.
Animals
;
Drugs, Chinese Herbal
;
administration & dosage
;
Gene Regulatory Networks
;
drug effects
;
Humans
;
Interleukin-6
;
genetics
;
metabolism
;
Male
;
Rats
;
Rats, Sprague-Dawley
;
Retinal Vein Occlusion
;
drug therapy
;
genetics
;
metabolism
3.Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report.
Annals of the Academy of Medicine, Singapore 2008;37(7):591-593
INTRODUCTIONWe report a case in which intravitreal bevacizumab and ranibizumab appeared to have effects in the contralateral, uninjected eye.
CLINICAL PICTUREAn 83-year-old man with macular oedema from branch retinal vein occlusion (BRVO) in the right eye developed neovascular macular degeneration in the left eye. Intravitreal bevacizumab in the left eye improved macular oedema in the right eye temporarily before it recurred. Subsequently, intravitreal ranibizumab in the left eye also resulted in significant reduction of macular oedema in the right eye.
OUTCOMEVision and macular oedema in the right eye improved.
CONCLUSIONBevacizumab and ranibizumab may have therapeutic effects in the uninjected eye, possibly because they may escape from the eye into the systemic circulation.
Aged, 80 and over ; Angiogenesis Inhibitors ; administration & dosage ; therapeutic use ; Antibodies, Monoclonal ; administration & dosage ; therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Eye ; drug effects ; Humans ; Injections ; Macular Edema ; drug therapy ; etiology ; Male ; Ranibizumab ; Retinal Vein Occlusion ; complications ; Treatment Outcome ; Vitreous Body
4.Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab.
Korean Journal of Ophthalmology 2010;24(3):179-181
A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluorescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improvement over the following several months.
Antibodies, Monoclonal/*administration & dosage
;
Disease Progression
;
Female
;
Fluorescein Angiography
;
Glaucoma, Neovascular/complications
;
Humans
;
Injections, Intraocular
;
Ischemia/diagnosis/*etiology/physiopathology
;
Middle Aged
;
Retinal Vein Occlusion/*complications/*drug therapy/physiopathology
;
*Retinal Vessels
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity/drug effects
;
Vitreous Body
5.Suspected Bacterial Endophthalmitis Following Sustained-release Dexamethasone Intravitreal Implant: A Case Report.
Mucella ARIKAN YORGUN ; Melek MUTLU ; Yasin TOKLU ; Hasan Basri CAKMAK ; Nurullah CAGIL
Korean Journal of Ophthalmology 2014;28(3):275-277
A 58-year-old man admitted to our opthalmology department with the complaint of branch retinal vein occlusion. He was treated with intravitreal Ozurdex in the right eye. Two days after the injection, the patient presented with ocular pain and the visual acuity was hand movement. A diagnosis of endophthalmitis was made. We performed emergent pars plana vitrectomy (PPV) and the implant was removed from the vitreous cavity using a retinal forceps. A combination of vancomycin 1.0 mg and amikacin 0.4 mg was injected intravitreally. However, because of the blurring in the vitreus one week after the procedure, phacoemulsification and a repeat PPV was performed. Five days after the last procedure the signs and symptoms of endophthalmitis were resolved. Our case demonstrated that endophthalmitis could develop after intravitreal implantation of Ozurdex. Surgical removal of the implant and immediate vitrectomy seems to be a useful treatment option in these cases.
Device Removal/methods
;
Dexamethasone/administration & dosage/*adverse effects
;
Diagnosis, Differential
;
Drug Implants/*adverse effects
;
Endophthalmitis/diagnosis/*etiology/surgery
;
Eye Infections, Bacterial/diagnosis/*etiology/surgery
;
Glucocorticoids/administration & dosage/adverse effects
;
Humans
;
Intravitreal Injections/adverse effects
;
Male
;
Middle Aged
;
Retinal Vein Occlusion/diagnosis/*drug therapy
;
Vitrectomy
6.Early versus Late Intravitreal Triamcinolone Acetonide for Macular Edema associated with Branch Retinal Vein Occlusion.
Joo Youn OH ; Je Hyun SEO ; Jae Kyoun AHN ; Jang Won HEO ; Hum CHUNG
Korean Journal of Ophthalmology 2007;21(1):18-20
PURPOSE: To compare the effect of early versus late intravitreal injection of triamcinolone in patients with macular edema due to branch retinal vein occlusion (BRVO). METHODS: Twenty eyes of 20 patients with macular edema from BRVO, including 10 with duration after onset of < or =3 months and 10 with duration of >3 months, were treated using a single intravitreal triamcinolone injection (4 mg/0.1 ml). Best-corrected visual acuity and foveal thickness by optical coherence tomography were measured 1, 3, and 6 months post-injection. RESULTS: In patients that received treatment after a disease duration of < or =3 months, visual acuity and foveal thickness significantly improved from baseline over 6 months of follow-up. However, in those with a duration of >3 months, improvements in visual acuity and foveal thickness, though apparent at 1 month, were not maintained at 3 and 6 months post-triamcinolone. CONCLUSIONS: Intravitreal triamcinolone is more effective in patients with BRVO who are treated earlier.
Visual Acuity/drug effects
;
Triamcinolone Acetonide/*administration & dosage/therapeutic use
;
Treatment Outcome
;
Tomography, Optical Coherence
;
Retinal Vein Occlusion/*complications
;
Middle Aged
;
Male
;
Macular Edema, Cystoid/chemically induced/*drug therapy/physiopathology
;
Humans
;
Glucocorticoids/*administration & dosage/therapeutic use
;
Fovea Centralis/drug effects
;
Female
;
Drug Administration Schedule
7.Cytomegalovirus Retinitis After Intravitreous Triamcinolone Injection in a Patient with Central Retinal Vein Occlusion.
Korean Journal of Ophthalmology 2008;22(2):143-144
To report a case of cytomegalovirus (CMV) retinitis after intravitreal injection of triamcinolone acetonide (IVTA). A 77-year-old woman with macular edema due to central retinal vein occlusion (CRVO) developed peripheral retinitis 4 months after IVTA. A diagnostic anterior chamber paracentesis was performed to obtain DNA for a polymerase chain reaction (PCR) test for viral retinitis. The PCR test was positive for CMV DNA. Other tests for infective uveitis and immune competence were negative. Four months after presentation, gancyclovir was intravitreously injected a total of 5 times, and the retinitis resolved completely. CMV retinitis is a rare complication of local immunosuppression with IVTA. It can be managed with timely injection of intravitreal gancyclovir until recovery from local immunosuppression.
Aged
;
Antiviral Agents/therapeutic use
;
Cytomegalovirus/genetics
;
Cytomegalovirus Retinitis/diagnosis/drug therapy/*etiology
;
DNA, Viral/analysis
;
Female
;
Ganciclovir/therapeutic use
;
Humans
;
Immunosuppressive Agents/*adverse effects
;
Injections
;
Macular Edema/drug therapy/etiology
;
Polymerase Chain Reaction
;
Retinal Vein Occlusion/complications/*drug therapy
;
Triamcinolone Acetonide/*adverse effects
;
Vitreous Body
8.Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion.
Peirong HUANG ; Zhengyu SONG ; Xiaodong SUN
Chinese Medical Journal 2014;127(16):3019-3023
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Aptamers, Nucleotide
;
therapeutic use
;
Bevacizumab
;
Humans
;
Macular Edema
;
drug therapy
;
Ranibizumab
;
Receptors, Vascular Endothelial Growth Factor
;
therapeutic use
;
Recombinant Fusion Proteins
;
therapeutic use
;
Retinal Vein Occlusion
;
drug therapy
;
Vascular Endothelial Growth Factor A
;
antagonists & inhibitors
;
Visual Acuity
;
drug effects
9.Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study.
Jing HOU ; Yong TAO ; Yan-rong JIANG ; Xiao-xin LI ; Lei GAO
Chinese Medical Journal 2009;122(22):2695-2699
BACKGROUNDBranch retinal vein occlusion (BRVO) is a common retinal vascular disorder of the elderly and both intravitreal triamcinolone acetonide (TA) and intravitreal bevacizumab were reported to be effective. The purpose of this study was to compare intravitreal bevacizumab with intravitreal TA for the treatment of macular edema resulting from BRVO.
METHODSThe retrospectively comparative interventional study included a bevacizumab group of 34 BRVO patients (1.25 mg bevacizumab) and a TA group of 34 BRVO patients (4.0 mg TA), and the two groups were matched by baseline best corrected visual acuity (BCVA). Examinations were designed to be carried out at 1 day, 3 days, 1 month, 2 months, 3 months, 6 months and 1 year after each injection. The mean follow-up was (148.43 +/- 130.56) days. Main outcome parameters were BCVA and morphometric measurements of the macula obtained by optical coherence tomography.
RESULTSIn all follow-ups, the mean changes of BCVA (LogMAR) between two groups were not significantly different (P > 0.10). Similarly, the rates of patients who got BCVA improvement > or = 2 lines or lost BCVA > or = 2 lines were not significantly different, either (P > 0.10). In both groups, compared with baseline, the mean central macular thickness (CMT) got reduction from 4 weeks to 1 year after initial injection, however, which lost statistical significance at 6-month follow-up in TA group (P = 0.25) and lost significance at 3-month and 6-month follow-up in bevacizumab group (P = 0.07, 0.21). The mean CMT between two groups differed at 3-month follow-up (P < 0.01), while almost kept parallel in other follow-ups (all P > 0.40). In TA group, retinal pigment epithelium tear occurred in 1 eye at 8 weeks after initial injection and 12 eyes (35.3%) got intraocular pressure > 21 mmHg. In bevacizumab group, no severe complications were observed.
CONCLUSIONFor BRVO, intravitreal bevacizumab versus intravitreal TA causes a similar increase in visual acuity and reduction of macular edema (except 3-month follow-up) with minor complications during 1 year.
Adult ; Aged ; Antibodies, Monoclonal ; administration & dosage ; adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Female ; Follow-Up Studies ; Humans ; Macular Edema ; drug therapy ; pathology ; Male ; Middle Aged ; Retinal Vein Occlusion ; complications ; Retrospective Studies ; Triamcinolone Acetonide ; administration & dosage ; adverse effects ; Visual Acuity ; Vitreous Body
10.Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice.
Qiqun ZENG ; Zhenzhen WU ; Hongxia DUAN ; Xuan JIANG ; Tao TU ; Di LU ; Yongting LUO ; Ping WANG ; Lina SONG ; Jing FENG ; Dongling YANG ; Xiyun YAN
Protein & Cell 2014;5(6):445-456
CD146 is a newly identified endothelial biomarker that has been implicated in angiogenesis. Though in vitro angiogenic function of CD146 has been extensively reported, in vivo evidence is still lacking. To address this issue, we generated endothelial-specific CD146 knockout (CD146(EC-KO)) mice using the Tg(Tek-cre) system. Surprisingly, these mice did not exhibit any apparent morphological defects in the development of normal retinal vasculature. To evaluate the role of CD146 in pathological angiogenesis, a xenograft tumor model was used. We found that both tumor volume and vascular density were significantly lower in CD146(EC-KO) mice when compared to WT littermates. Additionally, the ability for sprouting, migration and tube formation in response to VEGF treatment was impaired in endothelial cells (ECs) of CD146(EC-KO) mice. Mechanistic studies further confirmed that VEGF-induced VEGFR-2 phosphorylation and AKT/p38 MAPKs/NF-κB activation were inhibited in these CD146-null ECs, which might present the underlying cause for the observed inhibition of tumor angiogenesis in CD146(EC-KO) mice. These results suggest that CD146 plays a redundant role in physiological angiogenic processes, but becomes essential during pathological angiogenesis as observed in tumorigenesis.
Animals
;
CD146 Antigen
;
genetics
;
metabolism
;
Cells, Cultured
;
Endothelial Cells
;
cytology
;
metabolism
;
Female
;
Fibrosarcoma
;
metabolism
;
pathology
;
Male
;
Melanoma, Experimental
;
metabolism
;
pathology
;
Mice
;
Mice, Inbred C57BL
;
Mice, Knockout
;
NF-kappa B
;
metabolism
;
Neovascularization, Physiologic
;
drug effects
;
Phosphorylation
;
drug effects
;
Proto-Oncogene Proteins c-akt
;
metabolism
;
Retinal Vein
;
growth & development
;
pathology
;
Signal Transduction
;
drug effects
;
Transplantation, Homologous
;
Vascular Endothelial Growth Factor A
;
pharmacology
;
Vascular Endothelial Growth Factor Receptor-2
;
metabolism